PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31884211-0	2020	Sulforaphane prevents chromium-induced lung injury in rats via activation of the Akt/GSK-3beta/Fyn pathway.	sulforaphane	0-12	glycogen synthase kinase 3 beta	Rattus norvegicus	85-94	
31884211-5	2020	The results showed that SFN prevented Cr-induced oxidative stress, histopathological lesions, inflammation, apoptosis, and changes in protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK-3beta) levels in vivo and in vitro.	sulforaphane	24-27	glycogen synthase kinase 3 beta	Rattus norvegicus	161-192	
31884211-5	2020	The results showed that SFN prevented Cr-induced oxidative stress, histopathological lesions, inflammation, apoptosis, and changes in protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK-3beta) levels in vivo and in vitro.	sulforaphane	24-27	glycogen synthase kinase 3 beta	Rattus norvegicus	194-203	
31884211-8	2020	Collectively, this study demonstrates that SFN prevents K2Cr2O7-induced lung toxicity in rats through enhancing Nrf2-mediated exogenous antioxidant defenses via activation of the Akt/GSK-3beta/Fyn signaling pathway.	sulforaphane	43-46	glycogen synthase kinase 3 beta	Rattus norvegicus	183-192	
25724107-8	2015	Taken together, our findings suggested that SFN ameliorated experimental diabetic nephropathy, at least in part, via GSK3beta/Fyn/Nrf2 signaling pathway.	sulforaphane	44-47	glycogen synthase kinase 3 beta	Rattus norvegicus	117-125	
23784363-9	2014	Moreover, sulforaphane repressed the Ang II-induced phosphorylation of Akt, GSK3beta, mTOR, eIF4e, as well as of IkappaBalpha and NF-kappaB.	sulforaphane	10-22	glycogen synthase kinase 3 beta	Rattus norvegicus	76-84	
25724107-0	2015	Sulforaphane attenuation of experimental diabetic nephropathy involves GSK-3 beta/Fyn/Nrf2 signaling pathway.	sulforaphane	0-12	glycogen synthase kinase 3 beta	Rattus norvegicus	71-81	
25724107-5	2015	Simultaneously, the level of 8-oxo-deoxyguanosine, an indicator of oxidative damage, was markedly lowered in SFN-treated diabetic rats, together with a significant reduction in activity of the GSK-3beta/Fyn axis and an evident activation of Nrf2 signaling.	sulforaphane	109-112	glycogen synthase kinase 3 beta	Rattus norvegicus	193-202	
25724107-6	2015	Similarly, antifibrotic effects of SFN, parallel to enhanced inhibitory Ser9-phosphorylation of GSK3beta and Fyn/Nrf2 nuclear export/import, were observed in the cultured rat mesangial cells (RMC) exposed to high glucose.	sulforaphane	35-38	glycogen synthase kinase 3 beta	Rattus norvegicus	96-104	
25724107-7	2015	The salutary effects of SFN on high-glucose-stimulated RMC were abolished by overexpression of GSK3beta while being rescued by lithium chloride, a well-known GSK3beta inhibitor.	sulforaphane	24-27	glycogen synthase kinase 3 beta	Rattus norvegicus	95-103	
25724107-7	2015	The salutary effects of SFN on high-glucose-stimulated RMC were abolished by overexpression of GSK3beta while being rescued by lithium chloride, a well-known GSK3beta inhibitor.	sulforaphane	24-27	glycogen synthase kinase 3 beta	Rattus norvegicus	158-166